Obsidian Therapeutics
Obsidian Therapeutics raises $160.5M Series C at $750M valuation
Obsidian Therapeutics: Series C Funding Round
Obsidian Therapeutics has successfully raised $160.5M in Series C funding, reaching a valuation of $750M.
Company Overview
Clinical-stage biotech developing cell and gene therapies for cancer
Funding Details
The Series C round was led by New Enterprise Associates, with participation from Vida Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2014
- Employees: 100+
- Category: Biotech
Investment
Obsidian Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series C
- Vida Ventures: Verified investor in Series C
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free